AllQuantitative Report
Argus•January 13, 2021
Argus•January 13, 2021CYTK: Lowering target price to $20.00
Summary
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced mu
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Analyst Report: Biogen Inc.Apr 24, 2024 •
BIIB
- HALO: Raising target price to $41.00Apr 24, 2024 •
HALO
- LGND: Lowering target price to $73.00Apr 24, 2024 •
LGND
- CORT: Lowering target price to $18.00Apr 24, 2024 •
CORT
- The Argus Innovation Model PortfolioApr 23, 2024 •
GOOGL, AMAT, AAPL, ANET, CVX, ADI, AXON, URI, COST, V, LLY, SPGI, PANW, META, NVDA, SYK, BSX, ORCL, CBOE, PWR, MCK, NOW, ADBE, LYFT, SCHW, MCHP, ISRG, AMZN, ODFL, CRM